Drugmaker AstraZeneca raised its annual core profit outlook on Thursday, buoyed by strong demand for its oncology and rare blood disorder drugs.
The London-listed company now expects core earnings per share to increase by a low double-digit to low-teens percentage for the year, compared with an earlier forecast of high single-digit to low double-digit percentage growth.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.